Cederquist has advised Immunicum AB in connection with a directed share issue to selected Swedish and international institutional investors. Immunicum is leveraging its expertise in dendritic cell biology to develop novel, off-the-shelf, cell-based therapies for solid and blood-borne tumors. Immunicum receives approx. SEK 141.2 million before transaction costs through the share issue. For further information about the share issue and Immunicum, please refer to the company’s website, www.immunicum.se.
Cederquist’s team consisted of Fredrik Lundén, Henrik Wållgren and Louise Génetay.